US FDA To Generics Firms: Don't Forget Quality In Rush For 10-Month Review Goal
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has warned generic drug sponsors that application quality will be important as it prepares for a potential bolus of abbreviated new drug applications (ANDAs) that could arrive in October when review goals are enhanced again.